January 2020 Volume 16, Issue 1
Volume 16, Issue 1 | January 2020
January 2020
In this Issue
Preclinical
Meeting a new mechanism
Samumed publishes unique mechanism of action for SM08502Targeting tough tumors
Femtogenix payload platform has favorable toxicity profileA model replacement?
Heart-on-a-Chip technology predicts preclinical systolic, diastolic in-vivo observations for cardiac drug candidateKnowing the score
New application helps authors, publishers address heightened reproducibility and transparency standardsImmunic presents data on IMU-856 at Crohn’s and colitis conference
IMU-856 might address a root cause of inflammatory bowel disease without impairing immune systemClinical Trials
Phase 3 on the horizon
Oramed's oral insulin candidate shows efficacy in Phase 2b diabetes trialTriple combination study shows promise
BioLineRx’s combination regimen leads to improved disease control in pancreatic cancerADVM-022 success is no OPTICal illusion
Adverum’s wet AMD candidate helps maintain vision in Phase 1 trialResistance to Alzheimer’s is not futile
Troriluzole successfully advances past interim futility analysis in pivotal Phase 2/3 studyAntibody vs. Alzheimer’s disease
Alector announces Phase 1 data on AL002 at 12th annual CTAD meetingDiscovery
Collaboration “DUBbed” a success
Mission and AbbVie deal reaches milestone as partnership continuesMaking waves with macrophages
NTU Singapore scientists discover new key to promote insulin production in pre-diabetes patientsOnward and upward
Three companies will enter 2020 with support to launch new growthModels for seeing things more clearly
Two new cell models for ocular drug discovery could reduce the need for animal testingStreamlining CRISPR gene-editing workflows
Individual sgRNA and library collections expand Edit-R gene-editing platformEditor's Focus
Editor’s Focus: Double helix, double bind
Of all the areas where 'just because you can doesn't mean you should' ought to be a leading tenet, genomics is at the top of the list. The promise of gene editing must be partnered with caution regarding the ways it could be mishandled; we need to decide now which lines shouldn't be crossed, rather than backtracking after someone steps over them.Special Reports
Special Report on Gene Therapy: Finding the pathfinders
Researchers move beyond cut-and-paste to address genetic disordersFeature
SOT/ToxExpo 2020 Show Preview: A taste of toxicology
The ‘best in toxicological research’ makes its way to AnaheimResearch & Development
Aggravating atherosclerosis
Study of T cells sheds light on cardiovascular eventsOpen Targets finds differences in immune disease DNA
With strong financial backing from Open Targets, a battery of scientists is working to identify specific variations in DNA that correspond with different immune diseasesAkoya finds $50M more in financing
Funding will support continued commercialization of Akoya’s spatial biology platformsOral therapy for hemophilia
Bayer enters into collaboration with Children’s Hospital of Philadelphia on novel small-molecule drugsContract Services
Drugging the undruggable
Cresset Discovery Services contracted by PhoreMost to work on oncology protein targetDose CMO industry performing strongly
This despite challenges of increasingly complex drug production, says GlobalDataDiagnostics
Stepping up against sepsis
Companies ink agreement to develop rapid, point-of-care solution for diagnosing bloodstream infectionsCologuard mechanism tested for liver cancer
Test that has proven useful for non-invasive colorectal cancer screening leads to new possibilitiesDuo for diagnostics
Startup company Breakthrough Diagnostics performs clinical testing of LymPro test for Alzheimer’s diseaseBusiness & Government Policy
End of the road
Illumina and Pacific Biosciences announce termination of merger agreementOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsExpedeon and Abcam close transaction
With deal sealed, Expedeon changes name and shifts to DNA manufacturing and enzymes for diagnosticsFast-tracking the regulation submission process
Yseop and Litera partner up to help life-sciences companiesPatent Docs: More on patent-ineligibility from the Federal Circuit
The Federal Circuit continuse to expand the scope of patent-ineligible invention in its recent iNo Therapeutics LLC v. Praxair Distribution Inc. decision, relying on Justice Breyer's exhortation, in his Mayo Collaborative Serv. Inc. v. Prometheus Laboratories opinionCommentary
Out of order: For the better
Science is elusive and ever shifting, refusing to come into focus, and that is both its curse and its blessingCase study: Managing informatics challenges across distributed drug discovery projects
Collaboration between drug discovery groups from different sites, organizations and companies has become much more common, and distributing research can have profound advantages even as managing the process poses unique challenges
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
The unsung tools behind analytical testing success
Learn how fundamental laboratory tools like pipettes and balances support analytical precision.
Improving ALS research with pluripotent stem cell-derived models
Discover new advancements in modeling amyotrophic lateral sclerosis.
Automating 3D cell selection
Discover precise automated tools for organoid and spheroid handling.
